Evidence map›Paper›PMID 41899367›Full record

ReviewJournal of clinical medicine2026

Artificial Intelligence in Asthma and COPD: Current Status and Future Potential.

Federica Marrelli, Chiara Lupia, Saverio Nucera, Daniela Pastore, Paolo Zaffino, Carolina Muscoli, Girolamo Pelaia, Corrado Pelaia

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Federica MarrelliDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0009-0006-7653-9565
Chiara LupiaDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0009-0004-8786-3489
Saverio NuceraDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-0000-4015
Daniela PastoreDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.
Paolo ZaffinoDepartment of Experimental and Clinical Medicine, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-0219-0157
Carolina MuscoliDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-1047-4467
Girolamo PelaiaDepartment of Health Sciences, "Magna Graecia" University-Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-9288-8913
Corrado PelaiaDepartment of Medical and Surgical Sciences, "Magna Graecia" University-Catanzaro, Viale Europa-Località Germaneto, 88100 Catanzaro, Italy.ORCID 0000-0002-4236-7367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interest in artificial intelligence (AI) is rapidly growing. In healthcare, especially through machine learning and deep learning, AI is emerging as a promising tool to support the diagnosis, management, and prevention of lung diseases and to advance personalized care, although it requires large, well-structured datasets. Clinicians must learn how to integrate AI into routine practice for conditions such as asthma and chronic obstructive pulmonary disease (COPD), while ensuring patient safety and building trust in these tools. Chronic respiratory diseases are major global causes of morbidity and mortality and place a substantial burden on healthcare systems; among them, asthma and COPD are chronic disorders characterized by airway obstruction and inflammation. This review highlights the rapid advancement of AI, and it aims to explore the literature's evidence of its applicability in controlling chronic respiratory disorders, particularly in asthma and COPD. We conducted a narrative literature review by searching ScienceDirect, PubMed, and Google Scholar for English-language studies on artificial intelligence applications in asthma and COPD and by screening the references of relevant articles. The reviewed literature suggests that AI-based approaches are being applied across the asthma-COPD spectrum to support diagnosis and phenotyping, improve risk stratification and prediction of clinically relevant outcomes, and enable more continuous monitoring using heterogeneous data sources (e.g., clinical records, imaging, and digital health data). AI-based tools are poised to support clinicians in asthma and COPD across diagnosis, phenotyping, and monitoring; however, their safe implementation in routine care will require robust validation, transparency, and governance to ensure reliability and patient safety.

Indexed as

artificial intelligenceasthmaCOPDdeep learningmachine learning

Identifiers

PMID41899367
PMCPMC13028076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.